Tamara Lee
Psychiatric/Mental Health · Roseburg, ORNPI 1992720965
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.4%), consulting fees and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 49.7% of the total. Reporting peaked in 2021 at $2,382 and has fallen 91.9% since, to $193 in 2025. Among psychiatric/mental health clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 155 payments — averaging $25.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$375
- Alkermes, Inc.$331
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$315
- Axsome Therapeutics, Inc.$172
- Lundbeck LLC$144
- plus $614 from 11 others
What the payments were for
- Consulting fees$1,53039%
- Food & beverage$2,26858%
- Education$832%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MYCITE$1,530
How this compares
$3,881 in reported general payments places this provider in the 95th percentile of 540 psychiatric/mental health providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $83,332 |
| AuvelityDextromethorphan Hbr/Bupropion | 21 | $22,266 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $19,411 |
| DayvigoLemborexant | 15 | $5,981 |
| Aripiprazole | 59 | $5,770 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 94 | $5,468 |
| FetzimaLevomilnacipran Hcl | 11 | $5,281 |
| Olanzapine | 49 | $2,530 |
| Quetiapine Fumarate | 48 | $1,189 |
| Duloxetine Hcl | 51 | $1,125 |
| Methylphenidate Hcl | 21 | $945 |
| Doxepin Hcl | 33 | $902 |
| Clonazepam | 92 | $835 |
| Lamotrigine | 73 | $748 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 25 | $731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $81 | $83,33211 claims |
| Axsome Therapeutics, Inc.Auvelity | $172 | $22,26621 claims |
| Alkermes, Inc.Lybalvi | $331 | $19,41113 claims |
| AbbVieFetzima | $375 | $5,28111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 540 psychiatric/mental health providers in Oregon.
Other psychiatric/mental health in Roseburg
- Susan EllisRoseburg$14K
- Amber HobergHillsboro$1.9M
- Tina Matthews-HayesPortland$787K
- Carmen KosicekHillsboro$539K
- Johnni CanslerPortland$529K
- Jill CarterPortland$416K
- William BettsEugene$41K
- Michelle VoegelsPortland$29K
- Rance SmithKlamath Falls$15K
- Jennifer BehnkeMcMinnville$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.